Active Ingredient History
O6-Benzylguanine (O6-BG) is a synthetic derivative of guanine. It is an antineoplastic agent. It exerts its effect by acting as a suicide inhibitor of the enzyme O6-alkylguanine-DNA alkyltransferase which leads to interruption of DNA repair. O6-BG was used clinically in combination with the alkylating agent temozolomide for glioblastoma, however the combination was found to be overly toxic without adding significant benefit. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 3)
Choroid Plexus Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Craniopharyngioma (Phase 1)
DNA Mismatch Repair (Phase 1)
Ependymoma (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
HIV (Phase 1)
Hodgkin Disease (Phase 1)
Kidney Neoplasms (Phase 1)
Liver Neoplasms (Phase 1)
Lymphoma (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 1)
Multiple Myeloma (Phase 2)
Neoplasms (Phase 1)
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neuroblastoma (Phase 1)
Neuroectodermal Tumors (Phase 1)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 1)
Sarcoma (Phase 2)
Sezary Syndrome (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue